Overview

Evaluation of Therapeutic Drug Monitoring of Protease Inhibitors on Virologic Success and Tolerance of Highly Active Antiretroviral Therapy (HAART)

Status:
Terminated

Trial end date:
2005-03-01

Target enrollment:

Participant gender:

Summary

This Cophar2 study is a trial which evaluates repeated early therapeutic drug monitoring, from weeks 2 to 24, after the initiation of HAART including either indinavir/r, lopinavir/r or the new 625 mg formulation of nelfinavir twice-a-day (bid). If trough concentrations were out of the range given for each protease inhibitor (PI), the PI dose was adjusted.

Phase:

N/A

Details

Lead Sponsor:

French National Agency for Research on AIDS and Viral Hepatitis

Collaborator:

Hoffmann-La Roche

Treatments:

HIV Protease Inhibitors
Indinavir
Lopinavir
Nelfinavir
Protease Inhibitors
Ritonavir